HK1129394A1 - Hepatocyte growth factor (hgf) binding proteins - Google Patents
Hepatocyte growth factor (hgf) binding proteinsInfo
- Publication number
- HK1129394A1 HK1129394A1 HK09107469.8A HK09107469A HK1129394A1 HK 1129394 A1 HK1129394 A1 HK 1129394A1 HK 09107469 A HK09107469 A HK 09107469A HK 1129394 A1 HK1129394 A1 HK 1129394A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hgf
- growth factor
- binding proteins
- hepatocyte growth
- hepatocyte
- Prior art date
Links
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 title 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 title 1
- 102000023732 binding proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81071406P | 2006-06-02 | 2006-06-02 | |
US86046106P | 2006-11-21 | 2006-11-21 | |
PCT/US2007/012950 WO2007143098A2 (fr) | 2006-06-02 | 2007-06-01 | Protéines de liaison au facteur de croissance des cellules hépatiques (hgf) |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1129394A1 true HK1129394A1 (en) | 2009-11-27 |
Family
ID=38802082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09107469.8A HK1129394A1 (en) | 2006-06-02 | 2009-08-13 | Hepatocyte growth factor (hgf) binding proteins |
Country Status (16)
Country | Link |
---|---|
US (5) | US7659378B2 (fr) |
EP (2) | EP2380908A1 (fr) |
JP (2) | JP4560582B2 (fr) |
KR (1) | KR101196184B1 (fr) |
AR (1) | AR061170A1 (fr) |
AT (1) | ATE533787T1 (fr) |
AU (1) | AU2007254853B2 (fr) |
BR (1) | BRPI0712223A2 (fr) |
CA (1) | CA2654019A1 (fr) |
ES (1) | ES2378097T3 (fr) |
HK (1) | HK1129394A1 (fr) |
IL (2) | IL195038A0 (fr) |
MX (1) | MX2008015138A (fr) |
NO (1) | NO20085422L (fr) |
NZ (1) | NZ573819A (fr) |
WO (1) | WO2007143098A2 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR061170A1 (es) * | 2006-06-02 | 2008-08-06 | Aveo Pharmaceuticals Inc | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) |
JP4686634B2 (ja) * | 2006-06-02 | 2011-05-25 | アベオ ファーマシューティカルズ, インコーポレイテッド | 肝細胞成長因子(hgf)結合蛋白質 |
CA2691378A1 (fr) | 2007-07-02 | 2009-01-08 | Oncomed Pharmaceuticals, Inc. | Anticorps contre la r-spondine humaine et utilisation associee en vue de l'inhibition du signalement de beta-catenine et traitement du cancer |
US20090124022A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
US20090123946A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
SG190572A1 (en) * | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
WO2009148928A1 (fr) | 2008-05-29 | 2009-12-10 | Galaxy Biotech, Llc | Anticorps monoclonaux dirigés contre un facteur de croissance fibroblastique basique |
RU2010153578A (ru) * | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
CA2726087A1 (fr) * | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Immunoglobulines a deux domaines variables et leurs utilisations |
EP2313435A4 (fr) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3) |
RU2011104348A (ru) * | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
HUE028589T2 (en) * | 2008-07-10 | 2016-12-28 | Toray Industries | Pharmaceutical preparation for the treatment and prevention of cancer |
ES2523740T3 (es) | 2008-11-07 | 2014-12-01 | Galaxy Biotech, Llc | Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 |
JP2012508563A (ja) * | 2008-11-12 | 2012-04-12 | シェーリング コーポレイション | 抗IGF1R発現の増強のためのβGl−IGGイントロン |
US20120052064A1 (en) | 2009-04-17 | 2012-03-01 | Yuuki Ito | Anti-hgf antibody combinational cancer therapies |
UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
KR20120060877A (ko) * | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
KR20130100118A (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
CA2809433A1 (fr) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Immunoglobulines a deux domaines variables et leurs utilisations |
EP2643351A1 (fr) * | 2010-11-24 | 2013-10-02 | Glaxo Group Limited | Protéines multispécifique se liant à un antigène et ciblant hgf |
WO2013012747A1 (fr) | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Agents de fixation aux protéines rspo et leurs utilisations |
WO2013078223A1 (fr) * | 2011-11-23 | 2013-05-30 | Children's Hospital & Research Center Oakland | Anticorps anti-protéine liant le facteur h et procédés pour les utiliser |
TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對il-13及/或il-17之雙特異性結合蛋白 |
WO2013152252A1 (fr) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Polythérapie antinéoplasique |
JP6335896B2 (ja) | 2012-07-13 | 2018-05-30 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Rspo3結合剤およびその使用法 |
CA2890263C (fr) | 2012-11-01 | 2020-03-10 | Abbvie Inc. | Immunoglobulines a domaine variable double anti-vegf/dll4 et leurs utilisations |
EP2964673A4 (fr) * | 2013-03-14 | 2017-02-22 | Alder Biopharmaceuticals, Inc. | Anticorps dirigés contre hgf et compositions les contenant |
US9481725B2 (en) | 2013-03-14 | 2016-11-01 | Alderbio Holdings, Llc | Antibodies to HGF and compositions containing |
WO2014144280A2 (fr) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1β et/ou il -17 |
WO2015031578A1 (fr) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Dosage de hgf |
BR112016021383A2 (pt) | 2014-03-24 | 2017-10-03 | Genentech Inc | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo |
CN106714833A (zh) * | 2014-08-15 | 2017-05-24 | 昂考梅德药品有限公司 | Rspo1结合剂及其用途 |
US10064937B2 (en) | 2014-09-16 | 2018-09-04 | Oncomed Pharmaceuticals, Inc. | Treatment of dermal fibrosis |
US10550187B2 (en) | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
EP3209769B1 (fr) | 2014-10-24 | 2020-08-05 | The Board of Trustees of the Leland Stanford Junior University | Compositions et procédés pour induire la phagocytose de cellules positives de classe i du cmh et pour contrer la résistance aux agents anti-cd47/sirpa |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
WO2016205566A1 (fr) * | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Anticorps spécifiques anti-fzd7 et vaccins pour traiter le cancer et réguler la fonction de cellules souches |
CN109563153B (zh) | 2016-03-28 | 2022-09-02 | 加利福尼亚大学董事会 | 抗-ryk抗体及使用其的方法 |
NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
WO2018224951A2 (fr) * | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Anticorps multispécifiques modifiés et autres protéines multimères avec des mutations de région ch2-ch3 asymétriques |
JP7353187B2 (ja) | 2017-06-15 | 2023-10-05 | メモリアル スローン-ケタリング キャンサー センター | 抗l1-cam抗体およびその使用 |
MX2020005860A (es) | 2017-12-06 | 2020-09-09 | Avidity Biosciences Inc | Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica. |
WO2019217450A1 (fr) * | 2018-05-08 | 2019-11-14 | Rhode Island Hospital | Anticorps anti-chi3l1 pour la détection et/ou le traitement d'une stéatose hépatique non alcoolique / stéatohépatite non alcoolique et des complications subséquentes |
JP2022525703A (ja) * | 2019-03-20 | 2022-05-18 | ジャベリン・オンコロジー・インコーポレイテッド | 抗adam12抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法 |
JP2022543555A (ja) | 2019-08-12 | 2022-10-13 | インテアールエヌエー テクノロジーズ ビー.ヴイ. | miRNA-193aに関する新たな処置 |
US20230136088A1 (en) | 2020-02-28 | 2023-05-04 | Interna Technologies B.V. | miRNA-193a for Promoting Immunogenic Cell Death |
WO2021195469A1 (fr) | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions et procédés de traitement d'une dystrophie musculaire |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
US6498144B1 (en) * | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
US5707624A (en) * | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
WO2001034650A1 (fr) | 1999-11-09 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services | Combinaison d'anticorps monoclonaux hgf-sf |
WO2004006955A1 (fr) * | 2001-07-12 | 2004-01-22 | Jefferson Foote | Anticorps super humanises |
US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
US7220410B2 (en) * | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
JP5105874B2 (ja) | 2003-07-18 | 2012-12-26 | アムジエン・インコーポレーテツド | 肝細胞増殖因子に対する特異的結合因子 |
KR100556660B1 (ko) | 2003-11-11 | 2006-03-10 | 국립암센터 | Hgf의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
KR20080026562A (ko) | 2005-06-02 | 2008-03-25 | 갤럭시 바이오테크, 엘엘씨 | 항체를 이용한 뇌종양 치료 방법 |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
AR061170A1 (es) * | 2006-06-02 | 2008-08-06 | Aveo Pharmaceuticals Inc | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) |
JP4686634B2 (ja) * | 2006-06-02 | 2011-05-25 | アベオ ファーマシューティカルズ, インコーポレイテッド | 肝細胞成長因子(hgf)結合蛋白質 |
KR100829972B1 (ko) * | 2006-07-14 | 2008-05-16 | 재단법인서울대학교산학협력재단 | 항-hgf/sf 인간화 항체 및 이의 제조방법 |
-
2007
- 2007-06-01 AR ARP070102388A patent/AR061170A1/es not_active Application Discontinuation
- 2007-06-01 AU AU2007254853A patent/AU2007254853B2/en not_active Ceased
- 2007-06-01 BR BRPI0712223-3A patent/BRPI0712223A2/pt not_active IP Right Cessation
- 2007-06-01 EP EP11159440A patent/EP2380908A1/fr not_active Withdrawn
- 2007-06-01 AT AT07795607T patent/ATE533787T1/de active
- 2007-06-01 NZ NZ573819A patent/NZ573819A/en not_active IP Right Cessation
- 2007-06-01 KR KR1020087032082A patent/KR101196184B1/ko not_active IP Right Cessation
- 2007-06-01 ES ES07795607T patent/ES2378097T3/es active Active
- 2007-06-01 WO PCT/US2007/012950 patent/WO2007143098A2/fr active Application Filing
- 2007-06-01 US US11/757,094 patent/US7659378B2/en active Active
- 2007-06-01 CA CA002654019A patent/CA2654019A1/fr not_active Abandoned
- 2007-06-01 MX MX2008015138A patent/MX2008015138A/es active IP Right Grant
- 2007-06-01 EP EP07795607A patent/EP2029627B1/fr not_active Not-in-force
- 2007-06-01 JP JP2009513297A patent/JP4560582B2/ja not_active Expired - Fee Related
-
2008
- 2008-11-02 IL IL195038A patent/IL195038A0/en unknown
- 2008-12-30 NO NO20085422A patent/NO20085422L/no not_active Application Discontinuation
-
2009
- 2009-08-13 HK HK09107469.8A patent/HK1129394A1/xx not_active IP Right Cessation
- 2009-12-07 US US12/632,758 patent/US7935502B2/en not_active Expired - Fee Related
-
2010
- 2010-07-26 JP JP2010167648A patent/JP5528246B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-18 US US13/051,474 patent/US8268315B2/en not_active Expired - Fee Related
-
2012
- 2012-05-08 IL IL219655A patent/IL219655A0/en unknown
- 2012-08-20 US US13/589,652 patent/US8575318B2/en not_active Expired - Fee Related
-
2013
- 2013-09-27 US US14/039,912 patent/US20140178934A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1129394A1 (en) | Hepatocyte growth factor (hgf) binding proteins | |
HK1129395A1 (en) | Hepatocyte growth factor (hgf) binding proteins | |
IL245666A0 (en) | Interleukin-13 binding proteins | |
HK1217203A1 (zh) | 白介素- 的結合成員 | |
GB2449354B (en) | Binding protein | |
NO20082564L (no) | Hepatosyttvekstfaktorintronfusjonsproteiner | |
EP1776134A4 (fr) | Proteines de liaison de kinase c-met | |
EP1789451A4 (fr) | Protéines de liaison au complexe tie | |
GB0611116D0 (en) | Proteins | |
IL188671A0 (en) | Il-6 binding proteins | |
GB0601976D0 (en) | Proteins | |
GB0610140D0 (en) | Protein stability | |
GB0620735D0 (en) | Proteins | |
GB0420963D0 (en) | Hepatocyte | |
ZA200809483B (en) | Hepatocyte growth factor (HGF) binding proteins | |
EP2024516A4 (fr) | Proteines de perforine-2 | |
GB0511861D0 (en) | Proteins | |
GB0603878D0 (en) | Hepatocyte culture | |
GB0513653D0 (en) | Protein stability | |
GB0513505D0 (en) | Proteins | |
GB0514481D0 (en) | Proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160601 |